Is EDSA or SRZN more profitable?

Edesa Biotech has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Surrozen -4,810.50% N/A -154.08%

Do analysts rate SIGA or EDSA?

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 26.58%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is EDSA or IKT more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Inhibikase Therapeutics N/A -41.31% -38.98%

Do analysts recommend JMAC or EDSA?

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 26.58%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger valuation & earnings, JMAC or EDSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is JMAC or EDSA more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Edesa Biotech N/A -286.52% -75.36%

Is EDSA or ACIU more profitable?

Edesa Biotech has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% AC Immune -1,788.02% -125.26% -40.85%

Edesa Biotech (EDSA) Competitors

$6.81 -0.20 (-2.85%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$7.04 +0.23 (+3.36%)

As of 06:32 AM Eastern

Compare

EDSA vs. SRZN, SIGA, IKT, JMAC, and ACIU

Should you buy Edesa Biotech stock or one of its competitors? MarketBeat compares Edesa Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edesa Biotech include Surrozen (SRZN), Siga Technologies (SIGA), Inhibikase Therapeutics (IKT), Maxpro Capital Acquisition (JMAC), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.

How does Edesa Biotech compare to Surrozen?

Edesa Biotech (NASDAQ:EDSA) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Edesa Biotech has higher earnings, but lower revenue than Surrozen. Edesa Biotech is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Surrozen	$3.48M	76.10	-$242.03M	-$37.59	N/A

Edesa Biotech has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Edesa Biotech has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Surrozen	-4,810.50%	N/A	-154.08%

Edesa Biotech currently has a consensus price target of $5.00, suggesting a potential downside of 26.58%. Surrozen has a consensus price target of $42.00, suggesting a potential upside of 84.13%. Given Surrozen's higher possible upside, analysts plainly believe Surrozen is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Surrozen had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Surrozen and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Surrozen's score of 0.44 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
Surrozen	Neutral

Summary

Surrozen beats Edesa Biotech on 8 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Siga Technologies has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

In the previous week, Siga Technologies had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Siga Technologies and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Siga Technologies' score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Siga Technologies	Positive
Edesa Biotech	Very Positive

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 26.58%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Siga Technologies has a net margin of 21.58% compared to Edesa Biotech's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Edesa Biotech	N/A	-286.52%	-75.36%

Siga Technologies has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.74	$23.28M	$0.27	13.37
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Summary

Siga Technologies beats Edesa Biotech on 9 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Inhibikase Therapeutics?

Edesa Biotech (NASDAQ:EDSA) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inhibikase Therapeutics' return on equity of -41.31% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Edesa Biotech has higher earnings, but lower revenue than Inhibikase Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Inhibikase Therapeutics	$260K	995.30	-$48.26M	-$0.43	N/A

Edesa Biotech has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Inhibikase Therapeutics' score of 1.87 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
Inhibikase Therapeutics	Very Positive

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential downside of 26.58%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 175.51%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Summary

Inhibikase Therapeutics beats Edesa Biotech on 10 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Edesa Biotech (NASDAQ:EDSA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 26.58%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Maxpro Capital Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Maxpro Capital Acquisition's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Edesa Biotech	N/A	-286.52%	-75.36%

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Edesa Biotech had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for Maxpro Capital Acquisition. Edesa Biotech's average media sentiment score of 1.89 beat Maxpro Capital Acquisition's score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Edesa Biotech	Very Positive

Summary

Edesa Biotech beats Maxpro Capital Acquisition on 8 of the 11 factors compared between the two stocks.

How does Edesa Biotech compare to AC Immune?

Edesa Biotech (NASDAQ:EDSA) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

In the previous week, AC Immune had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat AC Immune's score of 0.95 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
AC Immune	Positive

Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential downside of 26.58%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 206.12%. Given AC Immune's higher probable upside, analysts clearly believe AC Immune is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Edesa Biotech has higher earnings, but lower revenue than AC Immune. Edesa Biotech is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
AC Immune	$4.31M	57.85	-$85.03M	-$0.82	N/A

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Edesa Biotech has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
AC Immune	-1,788.02%	-125.26%	-40.85%

Summary

AC Immune beats Edesa Biotech on 10 of the 16 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$67.53M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.08	20.85	27.11	24.26
Price / Sales	N/A	314.01	589.96	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	15.13	8.49	10.74	6.29
Net Income	-$7.19M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.71%	-3.56%	-2.11%	-1.35%
1 Month Performance	17.41%	6.31%	3.27%	-0.64%
1 Year Performance	209.55%	48.30%	26.31%	19.08%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	1.6237 of 5 stars	$6.81 -2.9%	$5.00 -26.6%	+225.8%	$67.53M	N/A	N/A	20	Positive News Gap Up
SRZN Surrozen	2.9119 of 5 stars	$23.01 -2.7%	$42.00 +82.5%	+166.5%	$274.70M	$3.48M	N/A	80	Negative News Short Interest Increase
SIGA Siga Technologies	0.7388 of 5 stars	$3.67 -2.1%	N/A	-46.7%	$268.96M	$94.57M	13.59	40
IKT Inhibikase Therapeutics	2.4795 of 5 stars	$2.05 +3.5%	$5.40 +163.4%	N/A	$261.42M	$260K	N/A	6	News Coverage
JMAC Maxpro Capital Acquisition	N/A	$19.36 -1.0%	N/A	+247.7%	$259.97M	N/A	N/A	2,021

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. SRZN, SIGA, IKT, JMAC, and ACIU

How does Edesa Biotech compare to Surrozen?

Summary

How does Edesa Biotech compare to Siga Technologies?

Summary

How does Edesa Biotech compare to Inhibikase Therapeutics?

Summary

How does Edesa Biotech compare to Maxpro Capital Acquisition?

Summary

How does Edesa Biotech compare to AC Immune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. SRZN, SIGA, IKT, JMAC, and ACIU

How does Edesa Biotech compare to Surrozen?

Do institutionals & insiders hold more shares of EDSA or SRZN?

Which has higher valuation & earnings, EDSA or SRZN?

Which has more risk and volatility, EDSA or SRZN?

Is EDSA or SRZN more profitable?

Do analysts prefer EDSA or SRZN?

Does the media refer more to EDSA or SRZN?

Summary

How does Edesa Biotech compare to Siga Technologies?

Which has more risk & volatility, SIGA or EDSA?

Does the media favor SIGA or EDSA?

Do analysts rate SIGA or EDSA?

Do insiders and institutionals have more ownership in SIGA or EDSA?

Is SIGA or EDSA more profitable?

Which has higher valuation and earnings, SIGA or EDSA?

Summary

How does Edesa Biotech compare to Inhibikase Therapeutics?

Do institutionals and insiders have more ownership in EDSA or IKT?

Is EDSA or IKT more profitable?

Which has higher earnings and valuation, EDSA or IKT?

Which has more volatility and risk, EDSA or IKT?

Does the media prefer EDSA or IKT?

Do analysts recommend EDSA or IKT?

Summary

How does Edesa Biotech compare to Maxpro Capital Acquisition?

Do analysts recommend JMAC or EDSA?

Which has stronger valuation & earnings, JMAC or EDSA?

Which has more risk and volatility, JMAC or EDSA?

Is JMAC or EDSA more profitable?

Do insiders & institutionals have more ownership in JMAC or EDSA?

Does the media prefer JMAC or EDSA?

Summary

How does Edesa Biotech compare to AC Immune?

Does the media prefer EDSA or ACIU?

Which has more risk and volatility, EDSA or ACIU?

Do analysts rate EDSA or ACIU?

Which has better earnings and valuation, EDSA or ACIU?

Do institutionals & insiders believe in EDSA or ACIU?

Is EDSA or ACIU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools